Hovione and IDC Launch Commercial Intranasal Drug Delivery Platform with Single-Use Dry Powder Device
核心洞察
Hovione and Industrial Design Consultancy Ltd (搜索) (IDC (搜索)) have completed device design and established manufacturing capabilities for their lead single-use nasal dry powder device, making it available for commercial partnerships.
The platform enables pharmaceutical partners to leverage existing capsule-filling infrastructure, simplifying development while reducing costs, risks, and shortening timelines to clinic and commercialization.
The integrated solution spans API development, particle engineering, formulation manufacturing, capsule filling, and device supply, with patent protection covering the platform technology.
Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (搜索) (IDC (搜索)) have announced that their Intranasal Drug Delivery (搜索) Platform has reached commercial readiness, with the lead single-use nasal dry powder device now available for pharmaceutical partnerships.
Platform Commercialization and Manufacturing Capabilities
The companies have completed device design and established initial manufacturing and supply capabilities, enabling pharmaceutical partners to leverage existing capsule-filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization.
The milestone marks the platform's transition from development to commercial availability, offering pharmaceutical partners a fully integrated solution spanning API development, advanced particle engineering, drug product manufacturing, and device supply.
Device Technology and Intellectual Property
The single-use nasal dry powder device incorporates a proprietary, patented mechanism designed for ease of use and manufacturability. Pre-loaded with a drug capsule, the device enables pharmaceutical partners to utilize existing capsule filling infrastructure, reducing complexity and cost while accelerating development timelines.
The platform is protected by a dedicated intellectual property portfolio covering the device's platform technology, which has successfully achieved initial patent grants. The device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability.
Integrated Development Approach
"This milestone marks an important step in the evolution of our collaboration with IDC (搜索) – from device innovation to a fully integrated intranasal drug delivery (搜索) platform," said Dr. Márcio Temtem, Vice President, Strategic Business Management at Hovione. "As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies."
The collaboration brings together complementary capabilities to deliver a fully integrated intranasal solution spanning API development and advanced particle engineering to formulation, capsule filling, drug product manufacturing, and device design and supply. This integrated approach reduces the need for technology transfers, streamlines development, and provides a single platform for pharmaceutical partners.
Multi-Dose Development and Future Applications
In parallel with the single-use device commercialization, Hovione and IDC (搜索) are advancing a multi-dose variant to further expand the platform's applicability across therapies and dosing regimens. Dr. Stephen Knowles, Managing Director at IDC, noted: "Our partnership with Hovione has already delivered a successful single-use device suitable for a range of therapies and our joint team can support pharma customers to use the device to bring new nasal therapies to market. Additionally, we are now well-advanced with the development of a multi-use device to support an even wider range of therapies and patient needs."
The platform supports targeted delivery across the nasal cavity (搜索), including the upper olfactory region (搜索), enabling rapid systemic absorption and potential nose-to-brain delivery pathways.
Industry Presentation and Technical Insights
Hovione will present additional insights on its Intranasal Drug Delivery (搜索) Platform at the Respiratory Drug Delivery 2026 conference as part of a company-sponsored workshop on integrated nasal powder development. The workshop, scheduled for May 12, 2026, at the Westin Kierland in Phoenix, Arizona, will provide an end-to-end perspective on developing next-generation nasal powder products.
The presentation will cover advanced formulation and particle engineering strategies for addressing key challenges in nasal delivery such as deposition, absorption efficiency, and formulation retention. Complementary in-vitro and analytical tools will also be discussed as critical enablers for guiding development and supporting regulatory readiness.